Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of infection from the virus by a staggering 96 percent. The California biopharmaceutical company said that its drug lenacapavir had “demonstrated superiority” over Truvada,
MIT researchers have developed a new HIV vaccination method that generates a strong immune response with just two doses, one ...
The Montgomery Advertiser on MSN1d
HIV stigma is on the decline for the first time in five years, new study findsHIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...
Louisville Public Media on MSN4d
This preventive drug could be a 'game changer' in ending the HIV epidemicIn newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...
Black gay and bisexual men made up about 38% of the estimated 37,981 new HIV diagnoses in the U.S. in 2022. The Centers for Disease Control and Prevention estimates that approximately 50% of these men ...
Through decades of pioneering work on fighting the spread of infectious diseases such as HIV, South African public health ...
An event in Palm Springs will feature experts discussing updates in HIV research, as well as those living with HIV sharing ...
Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...
One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, ...
HIV among young people remains a significant public health concern because the decline in new HIV infections among ...
Mpumalanga had the highest HIV prevalence in 2022 at 17.4%, with rural areas most affected. ART coverage increased, but ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback